Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.
Filetti M, Lombardi P, Falcone R, Giusti R, Giannarelli D, Carcagnì A, Altamura V, Scambia G, Daniele G. Filetti M, et al. Among authors: daniele g. Explor Target Antitumor Ther. 2023;4(6):1136-1144. doi: 10.37349/etat.2023.00187. Epub 2023 Dec 1. Explor Target Antitumor Ther. 2023. PMID: 38213541 Free PMC article.
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO 11 investigators. Pignata S, et al. Among authors: daniele g. Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14. Lancet Oncol. 2015. PMID: 25882986 Free article. Clinical Trial.
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Piccirillo MC, Gallo C, Perrone F. Pignata S, et al. Among authors: daniele g. J Clin Oncol. 2017 Oct 10;35(29):3347-3353. doi: 10.1200/JCO.2017.73.4293. Epub 2017 Aug 21. J Clin Oncol. 2017. PMID: 28825853 Clinical Trial.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators. Pignata S, et al. Among authors: daniele g. Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9. Gynecol Oncol. 2019. PMID: 30979589 Free article. Clinical Trial.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guizzaro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S. Daniele G, et al. Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24. Gynecol Oncol. 2019. PMID: 31029508 Clinical Trial.
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G. Lorusso D, et al. Among authors: daniele g. Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20. Expert Opin Emerg Drugs. 2020. PMID: 33040627 Review.
Newly diagnosed ovarian cancer: Which first-line treatment?
Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Among authors: daniele g. Cancer Treat Rev. 2020 Dec;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub 2020 Oct 9. Cancer Treat Rev. 2020. PMID: 33068886 Review.
285 results